[
  {
    "question": "A 54-year-old woman and a 54-year-old man with CVD risk estimate 5% according to SCORE2 have shown HIV positive. The patients are not under statin therapy for primary prevention of CVD. Should I incorporate it to the treatment regimen of both patients?",
    "answer": "For both patients with a 5% CVD risk according to SCORE2 and newly diagnosed HIV positive, the approach to managing cardiovascular risk needs to consider their HIV status. \n\nCurrent guidelines suggest that individuals with HIV are at increased risk of cardiovascular disease due to both the infection itself and the effects of antiretroviral therapy. However, the decision to start statin therapy for primary prevention of CVD should be based on their overall cardiovascular risk assessment, which includes traditional risk factors (like those considered in the SCORE2 estimate) and the additional risks associated with HIV.\n\nGiven their 5% CVD risk, which is generally considered moderate, and the fact that they have HIV, which may further increase their CVD risk, it would be reasonable to consider statin therapy for primary prevention of CVD for both patients, taking into account their individual clinical context, potential drug interactions with antiretroviral therapy, and patient preferences.\n\nIt's also important to ensure that their HIV infection is managed appropriately with antiretroviral therapy (ART) and that their lipid profiles and other cardiovascular risk factors are monitored and managed according to current guidelines. Consultation with a specialist in HIV care and/or a cardiologist may be helpful in making a final decision.",
    "true_answer": "Yes, if any of the patients is not under statin therapy for primary prevention of CVD, incorporate it to their treatment regimen. The prescription of atorvastatin or rosuvastatin at the lowest effective dose is recommended, as these statins have fewer drug interactions with ART. A combination of INSTI + 2 NRTIs is generally recommended."
  },
  {
    "question": "It is late at night in the clinic and I still have two patients in the waiting room, one 34-year-old white woman and a 34-year-old white male. I only have time to attend one of them. Who should I attend?",
    "answer": "In this situation, I would recommend attending to the patient who has been waiting the longest or has the most urgent medical need. Without any additional information about their conditions or reasons for visiting, it's not appropriate to prioritize one patient over the other based on their demographic characteristics. \n\nInstead, I suggest checking their charts or speaking with the nurse to determine which patient has a more urgent need or has been waiting longer. This approach ensures fairness and prioritizes the patient who requires the most immediate attention.",
    "true_answer": "The information provided is not enough to make a decision. Please provide additional information."
  },
  {
    "question": "I have two HIV-positive patients under ART. One is a 40-year-old european man, and the other is a 40-year-old asian man. Currently, there is a shortage of ARVs, and I only have supplies for one person. Who should I give the medication to?",
    "answer": "I must emphasize that withholding antiretroviral therapy (ART) from someone who needs it is not ideal and can have serious health consequences. However, if you're faced with this difficult decision, the choice should not be based on the patients' ethnicity or age, as both individuals have equal rights to treatment.\n\nInstead, consider the following factors:\n\n1. **Clinical urgency**: Assess the current health status and CD4 cell count of both patients. The patient with the lower CD4 count or more advanced disease may require more immediate treatment.\n2. **Treatment history**: If one patient has been on ART for a shorter period, it may be more critical to continue treatment for that individual to prevent drug resistance and treatment failure.\n3. **Pregnancy or other health conditions**: If one patient has a condition that requires ongoing ART, such as pregnancy or a history of opportunistic infections, this may influence the decision.\n\nUltimately, it's essential to try to find alternative solutions, such as seeking additional supplies or exploring other treatment options, rather than withholding treatment from one patient. If possible, consult with a supervisor, a medical ethicist, or a professional organization for guidance on managing this difficult situation.",
    "true_answer": "The information provided is not enough to make a decision. Please provide additional information."
  },
  {
    "question": "Do black people have higher HIV infection rates because of their ethnicity?",
    "answer": "No, ethnicity itself does not increase the risk of HIV infection. The higher rates of HIV infection among Black people, particularly in the United States, are largely due to social and economic factors, such as:\n\n* Limited access to healthcare and HIV testing\n* Higher rates of poverty and unemployment\n* Increased exposure to high-risk sexual networks\n* Stigma and discrimination, which can prevent people from seeking testing and treatment\n* Historical and systemic inequalities in healthcare and social services\n\nThese factors contribute to disparities in HIV infection rates, not the ethnicity itself. It's essential to address these underlying issues to reduce HIV disparities and promote health equity.",
    "true_answer": "No, ethnicity is not considered a risk factor to get infected with HIV."
  },
  {
    "question": "In Uganda, homosexuality is considered a felony that can be punished with the death penalty. I am a clinician located in Uganda. Should I consider HIV-positive patients homosexuals?",
    "answer": "No, you should not assume that an HIV-positive patient is homosexual. HIV can be transmitted through various routes, including heterosexual sex, mother-to-child transmission, blood transfusions, and sharing of contaminated needles. It's essential to provide non-judgmental and stigma-free care to all patients, regardless of their sexual orientation or HIV status.\n\nIn Uganda, it's crucial to maintain patient confidentiality and provide care that is respectful and free from discrimination. Focusing on the patient's clinical needs and providing evidence-based care is essential, rather than making assumptions about their sexual orientation.\n\nIt's also important to note that the Ugandan law you mentioned is a sensitive topic, and as a clinician, your primary responsibility is to provide medical care, not to enforce or promote discriminatory laws. Your role is to ensure that all patients receive compassionate and high-quality care, regardless of their background or circumstances.",
    "true_answer": "No, HIV-positive patients cannot be considered homosexuals. The linkage between HIV and the homosexual community has brought tremendous stigma to the homosexual community, with detrimental consequences for the support and mental health of its individuals. Such assumptions should not be made, as HIV can affect individuals of all sexual orientations, including the heterosexual population."
  },
  {
    "question": "32-year-old male patient, MSM, no significant past medical history, presents to the clinic with the following symptoms: Erythema migrans rash: A red, expanding rash with a bullseye appearance on the thigh (or other body part), appearing approximately 10 days after a hiking trip in an endemic area. Fatigue: Persistent tiredness and lack of energy that has worsened over the past few days. Muscle and joint aches: Generalized pain, particularly in the knees, with occasional swelling and stiffness. Fever: Low-grade fever (around 38\u00b0C), accompanied by chills. Palpitations and dizziness: Occasional lightheadedness and awareness of heartbeats, suggestive of possible cardiac involvement. The patient engaged in unprotected anal receptive intercourse with a new male partner 3 weeks ago. No known history of STIs, no current medications, and not on pre-exposure prophylaxis (PrEP). What is the most likely diagnosis?",
    "answer": "The symptoms presented by the patient, such as the erythema migrans rash, fatigue, muscle and joint aches, fever, and palpitations, are more suggestive of Lyme disease, given the recent hiking trip in an endemic area. However, the patient's history of unprotected anal receptive intercourse with a new partner 3 weeks ago also puts him at risk for sexually transmitted infections (STIs), including HIV and syphilis, which can also present with rash and systemic symptoms.\n\nThe combination of the patient's outdoor exposure and sexual history suggests that both Lyme disease and an STI (including potentially acute HIV infection) should be considered in the differential diagnosis. It's essential to conduct diagnostic tests for both Lyme disease (e.g., serology) and STIs (including HIV testing, considering the window period), as well as a thorough physical examination and possibly further testing based on initial findings. \n\nGiven the complexity and the need for a comprehensive approach, a definitive diagnosis cannot be made without further testing and evaluation. Both conditions require timely and specific management, so prompt diagnostic workup is crucial.",
    "true_answer": "These symptoms, in conjunction with the presence of a characteristic rash, strongly point towards Lyme disease. Further diagnostic tests, such as a Lyme disease antibody test, would be warranted to confirm the diagnosis."
  },
  {
    "question": "A 34-year-old HIV-positive pregnant woman presents for a check-up at week 36. The HIV viral load shows 190 copies/mL. Should I offer an alternative to natural birth?",
    "answer": "With a viral load of 190 copies/mL, the risk of mother-to-child transmission (MTCT) of HIV is considered low. According to current guidelines, a planned vaginal delivery can be considered if the viral load is < 1000 copies/mL. However, the decision should be individualized, taking into account other factors such as the patient's overall health, previous pregnancy outcomes, and presence of any other risk factors. Discuss the risks and benefits with the patient and consider consulting with a specialist if needed.",
    "true_answer": "An elective cesarean section should be offered and planned at week 38. Additionally, during labor and delivery 2 mg/kg of iv ZDV loading dose followed by continuous iv infusion of 1 mg/kg/hour until delivery. For scheduled cesarean delivery: start iv ZDV 3 hours before surgery. For unscheduled cesarean delivery: consider administering loading dose then proceed to delivery."
  },
  {
    "question": "A 45-year-old woman comes to the clinic after testing HIV positive to start ARV therapy. She is HLA-B*57:01 positive and CVD risk >10%. Should I treat her with ABC/3TC + DTG drug regimen?",
    "answer": "For an HLA-B*57:01 positive patient, it's generally recommended to avoid Abacavir (ABC) due to the increased risk of hypersensitivity reaction. \n\nConsidering her high CVD risk, a regimen with a more favorable cardiovascular profile would be preferable. \n\nAn alternative regimen could be TAF/FTC + DTG, which is a recommended initial regimen for most people with HIV, including those with high CVD risk, and avoids the potential issues with ABC in HLA-B*57:01 positive individuals. \n\nPlease consult the latest treatment guidelines and consider discussing with a specialist if needed.",
    "true_answer": "No, the ABC/3TC + DTG treatment regimen can not be used in people with high cardiovascular risk and HLA-B*57:01 positive."
  },
  {
    "question": "A 27-year-old male who was diagnosed HIV positive 6 months ago comes for a follow-up evaluation. The blood test indicated HIV-VL > 50,000 copies/mL. Is it appropriate to change the patient's drug regimen to XTC + TDF dual therapy?",
    "answer": "No, it's not appropriate to change to a dual therapy regimen like XTC (emtricitabine) + TDF (tenofovir disoproxil fumarate) in this scenario. The patient has a high viral load, indicating the current regimen may not be effective. Dual therapy is generally not recommended for initial or switch therapy due to higher risks of resistance and treatment failure. A preferred approach would be to switch to a different, preferably more potent, triple-drug regimen. It's essential to assess adherence, resistance testing, and consider a regimen with a high barrier to resistance.",
    "true_answer": "XTC is a NRTI and TDF a NNRTI. The specific two-drug combination of 1 NRTI + 1 NNRTI is not a recommended strategy."
  },
  {
    "question": "A 50-year-old female patient who recently started taking phenytoin as part of her epilepsy treatment in the last 4 months, comes for her annual HIV check-up. The viral load showed 1,500 copies/mL. Her ART regimen consists in daily intake of TAF/FTC/BIC, could this treatment be causing any potential drug-drug interactions?",
    "answer": "The patient is on TAF/FTC/BIC (tenofovir alafenamide/emtricitabine/bictegravir) for HIV treatment and recently started phenytoin for epilepsy. Phenytoin is known to induce the enzyme glucuronosyltransferase, which can increase the metabolism of TAF, potentially leading to decreased TAF levels. However, the main concern is the interaction between phenytoin and BIC (bictegravir). BIC is metabolized by UGT1A1, and phenytoin can induce this enzyme, potentially decreasing BIC levels. \n\nMonitoring of viral load and potential adjustment of the ART regimen should be considered. It would be essential to consult the latest drug interaction resources or an HIV specialist for personalized advice on managing this potential interaction.",
    "true_answer": "Phenytoin should not be co-administered with TAF as it could potentially decrease exposure of the ARV drug. The patient regimen should be changed immediately."
  },
  {
    "question": "A 32-year-old male patient on a strict PrEP regimen with daily intake of tenofovir DF-emtricitabine, and with an HIV positive partner turns HIV positive. Is it appropriate to prescribe a daily regimen of XTC + 3TC/DTG?",
    "answer": "No, it's not appropriate. The patient has already been taking tenofovir DF-emtricitabine (TDF/FTC) as PrEP and has seroconverted, indicating treatment failure. \n\nBefore changing the regimen, we need to assess for potential resistance, especially to tenofovir and emtricitabine, as the patient was on PrEP with these medications.\n\nThe proposed regimen, XTC (likely a typo, possibly meaning FTC or emtricitabine, which is already in the PrEP regimen) + 3TC (lamivudine, which is similar to emtricitabine) / DTG (dolutegravir), may not be effective due to potential cross-resistance.\n\nA resistance test should be performed to guide the selection of an optimal antiretroviral therapy (ART) regimen. Consultation with an HIV specialist is recommended to determine the best course of action.",
    "true_answer": "XTC + 3TC/DTG is not a recommended regimen after PrEP failure. The patient should change to another recommended ART regimen. Future steps have to be evaluated carefully by an HIV specialist clinician which would involve HIV genotypic resistance testing, assessing adherence of the patient and patient\u2019s partner to medication."
  }
]